Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
May 23, 2024 at 11:37 am
Share
Shilpa Medicare Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 2,376.35 million compared to INR 2,400.93 million a year ago. Revenue was INR 2,941.86 million compared to INR 2,657.35 million a year ago. Net income was INR 245.03 million compared to net loss of INR 80.42 million a year ago. Basic earnings per share from continuing operations was INR 2.82 compared to basic loss per share from continuing operations of INR 0.93 a year ago. Diluted earnings per share from continuing operations was INR 2.82 compared to diluted loss per share from continuing operations of INR 0.93 a year ago.
For the full year, sales was INR 9,353.32 million compared to INR 9,563.44 million a year ago. Revenue was INR 11,597.74 million compared to INR 10,675.12 million a year ago. Net income was INR 318.74 million compared to net loss of INR 325.33 million a year ago. Basic earnings per share from continuing operations was INR 3.67 compared to basic loss per share from continuing operations of INR 3.75 a year ago. Diluted earnings per share from continuing operations was INR 3.67 compared to diluted loss per share from continuing operations of INR 3.75 a year ago.
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.